Skip to main content
Equibles
ABT logo

ABT · Abbott Laboratories

Track ABT — free

Use ABT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$99.18 -1.77 (-1.75%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$174.90B
Shares
1.74B
Volume · Sep 30 2.68M Avg daily vol (3M) 9.76M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$100.95 Open$100.26 Day$99.48–101.07 52W close$82.56–134.59 Avg vol 30d8.4M Short int19.9M · 1.1% float · 2.6d Short vol43% Last earningsJul 16, 2026 DataJan 2020–Sep 2026 Filing10-Q · Jul 28

Up next

Next earnings call
Oct 15, 2026 Est · unconfirmed · in 2 wks
Latest filing: 10-Q
filed Jul 28, 2026
Q2 2026 earnings call transcript
call held Jul 16, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$45.13B
Trailing 12 months
Net income (TTM)
$6.28B
Trailing 12 months
Revenue growth YoY
+7.8%
Year over year
Operating margin
17.1%
Trailing 12 months
P / E (TTM)
28.3
Trailing earnings · reciprocal yield 3.5%
FCF yield
4.2%
TTM · current market cap
Return on invested capital
7.5%
Trailing 12 months
Net cash
−$26.75B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
0.0%
Year over year · fewer shares
Price change (1Y)
-24.2%
Trailing year
Short interest
1.1%
Latest settlement · 2.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 16 · calm Equity put/call 0.38
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −3%
below
Price vs 50-day avg −6%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 35%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −3%
trailing
YTD return −19%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $107 › 200d $104 — 50d above 200d
Institutional flow Distributing
-4% holders QoQ · +190 funds added
Insider flow Distributing
Net -$46.9M over 90 days · 100% sells
Short interest Falling
1.14% of float · ▼ -10.0% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,990 holders — mid 3-yr range
Squeeze score 45
elevated · 0–100
Fundamentals
Strong
Revenue growth +6%
Y/Y
EPS growth −51%
Y/Y
Free cash flow $7.4B
Valuation P/E 28.1
in line
Buyback $6.7B
remaining
Balance sheet $4.4B
net debt
Quant / Vol
risk profile
Moderate
Volatility 27%
annualized · 1-yr
Max drawdown −39%
past year
ATR 2.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Latest guidance · from the Earnings Call filed Jun 30, 2026
full year
Comparable sales growth Non-GAAP 6.5% – 7.5%
Adjusted earnings per share Non-GAAP $5.45 – $5.60
third quarter
Adjusted earnings per share Non-GAAP $1.38 – $1.46
going forward
Nutrition growth 2% – 4%
Diagnostics growth 7% – 8%
EPD growth 7% – 9%
MedTech growth 8% – 10%
Top line growth 6.5% – 8.5%
Guided vs delivered · last 4 settled
Diluted earnings per share under GAAP third-quarter 2024
guided $0.85 – $0.89
$0.94 Beat +8.0%
Diluted earnings per share under GAAP full-year 2024
guided $3.25 – $3.40
$7.64 Beat +129.8%
Diluted earnings per share under GAAP second-quarter 2024
guided $0.69 – $0.73
$0.74 Beat +4.2%
EPS 2021
guided at least $5.00
$3.94 Miss −21.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−3% Neutral
Price vs 50-day avg
−6% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
35% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $107 › 200d $104 — 50d above 200d
Institutional flow Distributing
-4% holders QoQ · +190 funds added
Insider flow Distributing
Net -$46.9M over 90 days · 100% sells
Short interest Falling
1.14% of float · ▼ -10.0% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,990 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $83 Now $101 · 35% Range high $135
vs 200-day avg -3% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABT
Abbott Laboratories
this stock
$174.90B -19.4% +5.7% 28.1 1.1%
MDT
Medtronic plc
 $113.38B -9.3% +8.4% 21.8 1.3%
SYK
Stryker Corp
 $104.47B -20.7% +11.2% 28.2 2.0%
BSX
Boston Scientific Corp
 $63.59B -54.0% +12.5% 17.8 3.2%
EW
Edwards Lifesciences Corp
 $49.74B +3.3% +11.5% 49.6 1.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
2,990
% held
80.5%
Net QoQ
+10.3M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,068
View
Short & Settlement
Short Interest Falling
Shares short
19.9M
Days to cover
2.6d
Change
-2.2M sh
View
Short Volume
Short vol %
43%
As of
Sep 29, 2026
Short Total
View
Fails to Deliver
FTD shares
17.7K
Value
$1.9M
As of
Sep 2, 2026
View
Off-Exchange
Off-exchange %
47.5%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$46.9M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
Richard Dean McCormick
Amount
$1.0K–$15.0K
Traded
Jul 30, 2026
View
Financials
Financials
Revenue (FY)
$44.3B
Net income (FY)
$6.5B
EPS diluted
$3.72
View
Buybacks
Authorized
$7.0B
Remaining
$6.7B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 20, 2026
This year
14
View
Proposed Sales
Value
$3.0K
Shares
27
Filed
Sep 2, 2026
View
Earnings & Events
Earnings Calls
Last call
Jul 16, 2026
View

Performance

5D 20D 120D MTD YTD
ABT -2.6% -8.5% -2.5% -8.5% -19.4%
SPY -1.2% -0.4% +13.1% -0.4% +12.1%
vs SPY -1.5% -8.2% -15.6% -8.2% -31.5%

Capital returns

Declared · upcoming
$0.63 / share · ex Oct 15, 2026
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Buyback program · as of Mar 31, 2026
Authorized
$7.00B
Spent (derived)
$300.00M
Remaining
$6.70B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1800 CUSIP 002824100 13F (30d) 87 filings 37 filers Visit website